Ken Griffin Intra Cellular Therapies, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$64.76 - $79.84 $2.46 Million - $3.03 Million	-38,000 Reduced 63.02%	22,300 $1.53 Million
Q1 2024 May 15, 2024	BUY	$64.37 - $75.65 $2.38 Million - $2.79 Million	36,900 Added 157.69%	60,300 $4.17 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $231,850 - $368,250	5,000 Added 27.17%	23,400 $1.68 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $36,463 - $44,869	700 Added 3.95%	18,400 $958,000
Q2 2023 Aug 14, 2023	SELL	$54.67 - $66.44 $1.21 Million - $1.47 Million	-22,200 Reduced 55.64%	17,700 $1.12 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $494,939 - $643,987	-11,300 Reduced 22.07%	39,900 $2.16 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $379,002 - $468,270	8,600 Added 20.19%	51,200 $2.71 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $183,610 - $257,957	4,300 Added 11.23%	42,600 $1.98 Million

402

90.5M

330K

306K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.35B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.